Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sagimet Biosciences Inc. (NASDAQ: SGMT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sagimet is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, and its filings offer detailed insight into this development strategy, capital structure, and risk profile.
Through Forms 8-K, Sagimet reports material events such as clinical trial updates, license agreements, accounting firm changes, at-the-market equity sales arrangements, and quarterly financial results. For example, recent 8-K filings describe positive Phase 1 pharmacokinetic data for a denifanstat and resmetirom combination, a global license agreement with TAPI for innovative forms of resmetirom active pharmaceutical ingredient to support a fixed-dose combination program, and financial results for recent quarters. Other 8-Ks outline changes in the company’s independent registered public accounting firm and the establishment of an at-the-market offering program for its Series A common stock.
Investors and analysts can use this page to locate Sagimet’s periodic and current reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on clinical development progress for denifanstat and TVB-3567, funding arrangements, and risk factors related to MASH and acne programs. Forms 4 and other ownership-related filings, when present, can be used to monitor insider transactions in SGMT shares.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the significance of new 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new Sagimet filings appear promptly, while AI-generated highlights can clarify complex topics such as licensing terms, at-the-market sales agreements, and clinical trial disclosures. This makes the SGMT filings page a practical starting point for reviewing Sagimet’s regulatory history and ongoing obligations.
Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.
The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.
Sagimet Biosciences announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025 and has updated its investor slide presentation. The press release is furnished as Exhibit 99.1 and the slide deck as Exhibit 99.2.
Both exhibits are described in the report as being furnished rather than filed, and therefore are not deemed filed or incorporated by reference into other SEC filings except if expressly referenced. Company representatives will use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors led by denifanstat. The company reported strong clinical progress: its Phase 2b FASCINATE-2 trial in MASH achieved both primary endpoints with statistically significant histologic and biomarker improvements, and denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis. License partner Ascletis reported denifanstat met all primary and secondary endpoints in a Phase 3 acne trial and plans submission in China.
Financially, Sagimet had $135.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 and expects these funds to support operations for at least 12 months. R&D spend rose sharply as programs advanced: six-month R&D expense was $22.59 million (up 95% year-over-year). Net loss for six months was $28.56 million, and the company had an accumulated deficit of $323.9 million. TVB-3567 received IND clearance in March 2025 and a first-in-human Phase 1 trial began in June 2025.
Sagimet Biosciences (SGMT) received an Amendment No. 1 to Schedule 13G from AP11 Limited and Ascletis Pharma Inc., dated 24 June 2025 and filed 29 June 2025. The filing reports beneficial ownership of 1,504,642 Series A common shares, equal to 4.9 % of the 30,674,855 shares outstanding as cited in Sagimet’s 10 June 2025 Form 8-K.
The reporting persons each claim sole voting and dispositive power over the entire position and report no shared power and no group status. Item 5 confirms “ownership of 5 percent or less,” meaning the investors are no longer 5 % holders under SEC rules. No additional transactions, control arrangements, or contingent rights are disclosed, and the document contains no risk factors, legal matters, or financial projections.
Overall, the amendment simply updates Sagimet’s ownership ledger, signalling that two related offshore entities now hold a sub-5 % passive stake without seeking influence over the issuer’s governance.